List of Bid Proposal Holders, June 16, 2015

List of Bid Proposal Holders

List of Bid Proposal Holders, July 21, 2015

List of Bid Proposal Holders

List of Bid Proposal Holders; Letting date: August 18, 2015

List of Bid Proposal Holders

List of Bid Proposal Holders; Letting date: August 18, 2015

List of Bid Proposal Holders

List of Bid Proposal Holders; Letting date: September 15, 2015

List of Bid Proposal Holders

List of Bid Proposal Holders; Letting date: October 20, 2015

List of Bid Proposal Holders

List of Bid Proposal Holders; Letting date: November 17, 2015

List of Bid Proposal Holders

List of Bid Proposal Holders; Letting date: December 15, 2015

List of Bid Proposal Holders

Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation.

Polyclonal intravenous immunoglobulin (IVIg) treatment reduces crossmatch positivity and increases rates of transplantation in highly sensitised patients (HS). We quantified the panel reactive antibody (PRA) by microlymphocytotoxicity (MLCC), and we analysed anti-HLA class I and class II IgG specific antibody repertoire by Luminex before and after IVIg infusion alone in HS patients awaiting kidney transplantation. Five patients received three monthly infusions of 1 g/kg of IVIg. Serum samples collected pre and post IVIg treatment were submitted for PRA analysis by MLCC. Anti-class I and anti-class II antibody specificities were then tested by Luminex. We focused on the anti-HLA class I and class II antibodies directed against HLA expressed by a previous graft. We also analysed the anti-HLA antibody repertoire in three patients who had not received IVIg infusion. The PRA level determined by MLCC decreased significantly in one of the five patients, dropping from 40% to 17%. The Luminex assay showed fluctuations of the anti-HLA antibody levels over time, but no significant longterm modifications of the anti-HLA antibody repertoire were observed, even in the patient with a strong and prolonged reduction of the PRA determined by MLCC. Our results show that IVIg at 1 g/kg is not sufficient to reduce PRA and does not modify the repertoire of specific anti-HLA antibody determined by Luminex.

List of Bid Proposal Holders; Letting date: January 10, 2016

List of Bid Proposal Holders

List of Bid Proposal Holders; Letting date: February 16, 2016

List of Bid Proposal Holders

List of Bid Proposal Holders; Letting date: March 15, 2016

List of Bid Proposal Holders

List of Bid Proposal Holders; Letting date: April 19, 2016

List of Bid Proposal Holders

List of Bid Proposal Holders; Letting date: May 17, 2016

List of Bid Proposal Holders

The international multidisciplinary consensus conference on multimodality monitoring in neurocritical care: a list of recommendations and additional conclusions : a statement for healthcare professionals from the neurocritical care society and the European society of intensive care medicine.

Careful patient monitoring using a variety of techniques including clinical and laboratory evaluation, bedside physiological monitoring with continuous or non-continuous techniques and imaging is fundamental to the care of patients who require neurocritical care. How best to perform and use bedside monitoring is still being elucidated. To create a basic platform for care and a foundation for further research the Neurocritical Care Society in collaboration with the European Society of Intensive Care Medicine, the Society for Critical Care Medicine and the Latin America Brain Injury Consortium organized an international, multidisciplinary consensus conference to develop recommendations about physiologic bedside monitoring. This supplement contains a Consensus Summary Statement with recommendations and individual topic reviews as a background to the recommendations. In this article, we highlight the recommendations and provide additional conclusions as an aid to the reader and to facilitate bedside care.